Skip to main content
Premium Trial:

Request an Annual Quote

Cellzome Hits Second Milestone in GSK Epigenetics Collaboration


Proteomics firm Cellzome said this week that it has hit a second milestone in its epigenetics collaboration with GlaxoSmithKline.

Achievement of the milestone, which triggered a payment of an undisclosed amount, comes two months after the company reached its first milestone in the collaboration. Signed in March 2010, the agreement calls for Cellzome to use its Episphere platform to screen for epigenetic drug targets related to undisclosed immuno-inflammatory diseases (GWDN 03/10/2010).

The deal netted the company a $45 million upfront payment and the potential to earn more than $645 million in milestone payments.

In January, Cellzome published a study in Nature Biotechnology using the Episphere platform to demonstrate that histone deacetylase, or HDAC, inhibition varies depending on the protein complex with which the target HDAC is associated – a finding with implications for the discovery of potential epigenetic drug targets (PM 01/28/2011).

That work was part of a proprietary effort by the company and not part of the GSK agreement, chief scientific officer David Simmons told ProteoMonitor. However, he added, Cellzome "is open to collaborating with other companies in that space."

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.